Facile SERS-active chip (PS@ Ag/SiO2/Ag) for the determination of HCC biomarker
Facile SERS-active chip (PS@ Ag/SiO2/Ag) for the determination of HCC biomarker
复制标题
用于测定 HCC 生物标志物的简便 SERS 活性芯片 (PS@Ag/SiO2/Ag)
DOI：
10.1016/j.snb.2018.05.139
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Wang Yaxin
中科院分区：
文献类型：
--
作者：
Zhang Yongjun;Sun Huanhuan;Gao Renxian;Zhang Fan;Zhu Aonan;Chen Lei;Wang Yaxin
肝细胞癌是世界范围内最致命的疾病之一，近年来的研究引起了人们的极大关注。早期诊断对快速控制和预防该病具有重要意义。到目前为止，在各种检测方法中，基于表面增强拉曼散射(SERS)的检测方法因其高选择性和高灵敏度而被认为是最具吸引力的策略。在这项研究中，我们设计了一种新型的SERS活性芯片用于检测肝癌生物标志物Lens culinaris凝集素反应性甲胎蛋白AFP-L3，该芯片采用不同大小的二维非紧密堆积的聚苯乙烯胶体球阵列@Ag/SiO_2/Ag壳(PS@Ag/SiO_2/Ag)复合结构作为SERS活性芯片，以5，5-二硫双(琥珀酰亚胺-2-硝基苯甲酸酯)标记的Ag/SiO_2/Ag表面为SERS探针。结果表明，甲胎蛋白-L3的浓度与DSNB的拉曼强度比I1390/I1074具有良好的线性关系，相关系数R2= 0.997。此外，当该芯片用于甲胎蛋白-L3浓度在0.078-8 ng/m L范围内时，检测下限(3σ)被确定为3 ng/m L。用该方法测定了3例肝病患者血清中的AFP-L3，显示了其在临床诊断中的应用潜力。
Hepatocellular carcinoma (HCC), which is one of the deadliest diseases worldwide, has drawn significant attention in recent research. Early diagnosis is important for the quick control and prevention of the disease. Until now, among the various detection methods, the strategies based on surface-enhanced Raman scattering (SERS) are considered the most attractive owing to the high selectivity and sensitivity. In this investigation, we designed a novel type of SERS-active chip for detecting the HCC biomarkerLens culinaris agglutinin-reactive Alpha-fetoprotein, AFP-L3, which utilizes a two-dimensional non-close-packed polystyrene colloid sphere arrays@Ag/SiO2/Ag shell (PS@Ag/SiO2/Ag) composite structure with different sizes as the SERS-active chip and an antibody-conjugated Ag/SiO2/Ag surface labeled with 5,5-Dithiobis (succinimidyl-2-nitrobenzoate) (DSNB) as the SERS probe. A good linear relationship between the concentration of AFP-L3 and the Raman intensity ratio I1390/I1074of DSNB was obtained, with the correlation coefficient R2= 0.997. Moreover, when the proposed SERS-active chip was utilized over the range of AFP-L3 concentrations 0–8 ng/mL, the limit of detection (3σ) was determined to be 0.078 ng/mL. The developed method was applied to the determination of AFP-L3 in three serum samples collected from patients diagnosed with liver disease, demonstrating its potential for application in clinical diagnosis.